Dynavax Technologies Corporation
Dynavax Technologies — Investor Presentation (August 2025)
22 slides from Dynavax Technologies's investor presentation, Aug 21, 2025
Slide 1: Corporate Presentation
Corporate Presentation Using Proven, Innovative Adjuvant Technology to Help Protect the World Against Infectious Diseases August 2025 Nasdaq: DVAX Exhibit 99.2
Slide 2: Forward-looking statements
Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about Dynavax's financial results and market share as of and for the quarter end
Slide 3: Executing on Our Strategy: Q2'25 Highlights
Executing on Our Strategy: Q2’25 Highlights Achieve HEPLISAV-B® Quarterly Sales Record Net product revenue: $92M up 31% YoY vs. $70M in Q2’24 Total U.S. quarter end market share: ~45% vs. ~42% in Q2’24 Long-term guidance: US adult Hepatitis B vaccine market expected to peak at +$900M by 2030; HEPLIS
Slide 4: Our Core Strategic Priorities
Maximizing HEPLISAV-B’s Commercial Potential Achieve at least 60% total market share by 2030 Maximize total addressable market focused on top retailers and IDNs based on the ACIP Universal Recommendation Leverage foundational commercial asset to support company growth and pipeline development Advan
Slide 5: CpG 1018: Leveraging Our Proven Adjuvant Across Pipeline
CpG 1018: Leveraging Our Proven Adjuvant Across Pipeline Proprietary CpG 1018 adjuvant selectively activates TLR9, an important toll-like receptor that elicits the body’s innate immune response when invading pathogens are introduced. Clinically Proven Profile Faster and consistently higher rates of
Slide 6: HEPLISAV-B Clinical Outcomes
Primary endpoint Primary endpoint HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted] Clinical Outcomes Higher and faster rates of protection HEPLISAV-B provided significantly higher rates of protection than Engerix-B at every time point in clinical trials HEPLISAV-B provided significantly h
Slide 7: Continued HEPLISAV-B Growth: Revenue & Market Share
Continued HEPLISAV-B Growth: Revenue & Market Share HEPLISAV-B Vaccine Annual Net Product Revenue ($M)2 Record Annual Revenue In 2024 Source: Internal data and company estimates. 1Quarter End market share data are for the Q2 of each year and do not reflect interim periods. 2. Dynavax financial repor
Slide 8: HEPLISAV-B Market Opportunity Expected to Surpass $900M in U.S. by 2030
Source: Internal data and company estimates. Not independently verified. 1Based on 2024 U.S. adult Hepatitis B vaccines net sales, adjusted for company estimates regarding HEPLISAV-B dosing regimen and pricing. 2Internal estimate. Segment expansions assumes 50% of ACIP universal growth from Retail,
Slide 9: U.S. Hep B Vaccine Sales Expected to Surpass $900M by 2030
U.S. Hep B Vaccine Sales Expected to Surpass $900M by 2030 HEPLISAV-B is the market share leader in the largest projected growth segment (Retail Pharmacy) © Copyright DYNAVAX 2025 2030 Projected Market Size: >$900M2 2024 Market Size: ~$615M1 Dialysis4 Dialysis4 | HEPLISAV-B Market Share Q2 2025 Mark
Slide 10: Vaccine Development Pipeline
Vaccine Development Pipeline © Copyright DYNAVAX 2025 | Abbreviations: BLA, Biologics License Application; IND, Investigational New Drug. Program IND-enabling Phase 1 Phase 2 Phase 3 BLA Review Partner Planned Milestones Shingles Vaccine Z-1018 Wholly owned by Dynavax Reported positive top-line Part
Slide 11: Shingles Vaccine Program
| 1Package Insert - SHINGRIX (fda.gov). 2Based on Full Year 2024 Shingrix net sales. New Options Needed Current Market-Leading Vaccine Associated with Adverse Events1 © Copyright DYNAVAX 2025 Herpes Zoster (shingles) is an extremely painful consequence of the reactivation of a latent varicella-zoste
Slide 12: Phase 1/2 Study Design (Part 1)
Phase 1/2 Study Design (Part 1) © Copyright DYNAVAX 2025 | Shingles Vaccine Program Safety, Tolerability, and Immunogenicity of Zoster-1018 Compared to Shingrix® Randomized, active-controlled, dose-escalation trial Dose-ranging of Dynavax-produced gE (3 levels, each with 6000 mg CpG 1018 ± alum) at
Slide 13: Z-1018 demonstrated comparable immunogenicity to Shingrix
Selected the 100 mcg dose of gE antigen, adjuvanted with CpG 1018 and alum, and using an 8-week dosing interval, to advance into Part 2 of the Phase 1/2 trial. Topline Immunogenicity Results Summary1 © Copyright DYNAVAX 2025 | Vaccine Response Rate (VRR)2 Anti-gE Antibodies CD4+ T cells Composite Z-
Slide 14: Topline Immunogenicity Results Summary (cont.)
Topline Immunogenicity Results Summary1 (cont.) © Copyright DYNAVAX 2025 | Anti-gE IgG Antibodies Geometric Mean Concentration Anti-gE IgG Antibodies Geometric Mean Fold Increase Activated CD4+ T-cells Median Frequencies Z-1018 100 mg 8-wk dosing interval Without alum With alum Shingrix Z-1018 100 m
Slide 15: Topline Tolerability Results Summary
Topline Tolerability Results Summary1 © Copyright DYNAVAX 2025 | Local PIRs, (%) Systemic PIRs, (%) Z-1018 100 mg (n=40) Z-1018 100 mg + alum (n=40) Shingrix (n=38) Z-1018 100 mg (n=40) Z-1018 100 mg + alum (n=40) Shingrix (n=38) 7 (17.5%) 5 (12.5%) 20 (52.6%) 7 (17.5%) 11 (27.5%) 24 (63.2%) Tolerab
Slide 16: Path to Establishing Proof-of-Concept for a Best-in-Class Shingles Vaccine
| Path to Establishing Proof-of-Concept for a Differentiated and Best-in-Class Shingles Vaccine © Copyright DYNAVAX 2025 Key Trial Objectives / Next Steps PHASE 1 CLINICAL TRIAL Established initial proof-of-principle for CpG 1018-adjuvanted shingles vaccine Demonstrated similar immunogenicity to Shi
Slide 17: Additional Pipeline Programs
Additional Pipeline Programs © Copyright DYNAVAX 2025 | Corporate updates Clinical & Preclinical Pipeline finance Commercial: hepLisav-B Pandemic Influenza Adjuvant One of the most persistent and unpredictable global health threats Opportunity: Adjuvants, like CpG 1018, play an essential role in pan
Slide 18: Financial Summary
Financial Summary 1Adjusted EBITDA is a non-GAAP financial measure. Additional information regarding our use of non-GAAP financial measures is included in the Appendix to this presentation and in our press release dated August 7, 2025, which is accessible in the Investors section of our website at w
Slide 19: Executing on Our Strategy: Q2'25 Highlights
Executing on Our Strategy: Q2’25 Highlights © Copyright DYNAVAX 2025 | Achieve HEPLISAV-B® Quarterly Sales Record Net product revenue: $92M up 31% YoY vs. $70M in Q2’24 Total U.S. quarter end market share: ~45% vs. ~42% in Q2’24 Long-term guidance: US adult Hepatitis B vaccine market expected to pea
Slide 20: Thank you
Thank you August 2025 Nasdaq: DVAX
Slide 21: Non-GAAP Financial Measures: Adjusted EBITDA
To supplement our financial results presented on a GAAP basis, we have included information about Adjusted EBITDA, a non-GAAP financial measure. We believe the presentation of this non-GAAP financial measure, when viewed with our results under GAAP and the accompanying reconciliation, provide analys
Slide 22: Reconciliation of GAAP Net Income (Loss) to Adjusted EBITDA
Dynavax Technologies Corporation Reconciliation of GAAP Net Income (Loss) to Adjusted EBITDA (In Thousands) (Unaudited) © Copyright DYNAVAX 2025 |
Dynavax Technologies — Investor Presentation (August 2025) on 6ix